ArticleThe Journal of infectious diseases2025
Use of Dog Serologic Data for Improved Understanding of Coccidioidomycosis: A One Health Approach.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intent to Accept a Valley Fever Vaccine for Humans and Dogs and Factors Influencing Intended Uptake: A Cross-Sectional Survey in Two Endemic Regions.Journal of fungi (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCoccidioidomycosis (Valley fever) occurs when animals and humans inhale spores of Coccidioides spp, soil-dwelling fungi of the southwestern United States (US). The spatial epidemiology of coccidioidomycosis is poorly understood due to irregular detection of Coccidioides in soil, disease underdiagnosis, and lack of nationwide mandatory reporting. Data on seroreactivity to Coccidioides among dogs-which are highly susceptible to coccidioidomycosis, widespread across the US, and have limited travel-may strengthen our understanding human disease risk.
methodsWe analyzed serologic test results for 834 899 dogs between 2012 and 2022 from all known diagnostic laboratories conducting serologic testing for anti-Coccidioides antibodies in dogs in the US. We used testing date and county-level location data to estimate spatial and temporal trends in incidence and test positivity for dogs and compared them to human surveillance data.
resultsThe overall seropositivity rate among tested dogs was 37.6% (313 829/834 899). Average test positivity rates in states with ≥0.5 tests per annum per 10 000 households were 35.4% (Texas) to 74.1% (Montana). For these states, average annual incidence per 10 000 households was as follows: Arizona (86.8), New Mexico (0.89), Nevada (0.78), California (0.75), Montana (0.63), Colorado (0.41), Oregon (0.41), Texas (0.38), Idaho (0.37), Wyoming (0.34), Utah (0.32), and Washington (0.26). Human incidence in California and Arizona between 2012 and 2022 was significantly correlated with dog incidence (ρ = 0.75 and ρ = 0.65, respectively). The distribution of seropositive dogs expanded from 76 of 3144 counties (2.4%) in 2012 to 390 in 2022 (12.4%).
conclusionsFurther investment in human diagnostic infrastructure and provider knowledge may ameliorate significant underrecognition of this emerging fungal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.